Global law firm Clifford Chance has advised Heilpflanzenwohl AG on the acquisition of two OTC products, “Döderlein” and “Omniflora”, from Haleon Sarl. The project also included in-licensing name, brand and image rights from Haleon UK IP Limited and transferring production and supply contracts and quality assurance agreements from Haleon Sarl to Heilpflanzenwohl AG. The parties have agreed not to disclose any details of the purchase price. Clifford Chance is also advising Heilpflanzenwohl group on developing marketing strategies for the new products.

The Heilpflanzenwohl group, based in Zug, Switzerland, and with a subsidiary in Berlin, develops and markets innovative medical and medicinal products based on natural active ingredients.

The UK company Haleon was established in July 2019 as a joint venture between the consumer healthcare divisions of GlaxoSmithKline and Pfizer. In July 2022, the company was spun off and noted on the London Stock Exchange.

The Clifford Chance team advising Heilpflanzenwohl on this transaction was led by partner Gunnar Sachs (Corporate/Healthcare, Düsseldorf) and comprised partner Stefan Richter (IP, Düsseldorf), counsel Carolin Kemmner and Alison Evans, senior associate Caroline Giesen and associate Annabel Joschko (all Corporate/Healthcare, Düsseldorf), partners Gareth Camp and Stephen Reese and senior associates Niall O’Shea and Alex Walker (all Corporate, London).